Mountain Valley MD (MVMD) AI Stock Analysis

• Market Cap: C$5.29M
• Dividend Yield: N/A
• Average Volume (3M): 205.59K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.42
• Revenue Growth: -46.59%
• EPS Growth: 8.26%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): >-0.01
• Shares Outstanding: 352,354,950
• 10 Day Avg. Volume: 152,980
• 30 Day Avg. Volume: 205,595
• PEG Ratio: 0.14
• Price to Book (P/B): 3.44
• Price to Sales (P/S): 177.77
• P/FCF Ratio: -2.23
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: C$0.02 ▼(-25.00% Downside)

The score is held down primarily by weak financial performance (minimal/declining revenue, large losses, persistent negative operating and free cash flow, and a reduced equity cushion). Technicals are mixed but the stock remains below key moving averages, and valuation is constrained by unprofitability and no dividend support. A positive corporate update on Agrarius trial results provides some upside potential but is not enough to offset current financial risk.

Positive Factors

Debt-Free Status

Being debt-free provides financial flexibility and reduces risk, allowing the company to focus on strategic investments and growth opportunities without the burden of interest payments.

Innovative Health Solutions

The company's focus on innovative health solutions positions it well in the pharmaceutical and nutraceutical sectors, potentially driving long-term growth through unique product offerings.

Scalable Solutions

By developing scalable and cost-effective health solutions, MVMD can expand its market reach and improve profitability, particularly in emerging markets where cost is a critical factor.

Negative Factors

Negative Profitability

Consistent losses and negative profit margins indicate challenges in achieving sustainable profitability, which could hinder long-term financial health and growth potential.

Declining Revenue

Declining revenue trends suggest instability in business operations, potentially affecting the company's ability to invest in R&D and maintain competitive positioning.

Negative Cash Flow

Negative cash flow highlights liquidity issues, limiting the company's ability to cover operational expenses and invest in future growth, posing a risk to long-term viability.

Mountain Valley MD Business Overview & Revenue Model

Company Description

Mountain Valley MD Holdings Inc., through its subsidiary, Mountain Valley MD Inc., operates as a health and wellness company. The company engages in the implementation and licensing of its technologies to pharmaceutical, vaccine, and nutraceutical third parties. It offers Quicksome oral drug formulation and delivery technologies; Quicksol solubility formulation technology; and dose sparing adjuvant. In addition, the company is developing IM032 for the treatment of male beagle dogs for comparing intramuscular and subcutaneous dosing. Mountain Valley MD Holdings Inc. is headquartered in Concord, Canada.

How the Company Makes Money

Mountain Valley MD makes money through the commercialization of its proprietary health solutions. The company generates revenue from the sale of its pharmaceutical and nutraceutical products, leveraging its unique delivery systems and formulations. Additionally, MVMD may establish partnerships with other pharmaceutical firms to co-develop or license its technologies, which can provide significant revenue streams through licensing fees, royalties, and milestone payments. The company's focus on scalable and cost-effective solutions contributes to its earnings potential in both emerging and established markets.

Mountain Valley MD Financial Statement Overview

Summary

Mountain Valley MD faces significant financial challenges, with consistent losses, decreasing revenues, and negative cash flows. While the debt-free capital structure is a positive, the lack of profitability and cash generation poses substantial risks. Improvement in revenue streams and cost management is crucial for future stability.

Income Statement

Mountain Valley MD shows a concerning trend in its income statement with persistently negative net and gross profit margins. The TTM data indicates a gross loss and a significant net loss relative to revenues, suggesting challenges in revenue generation and cost management. Revenue growth has been erratic, with a decline from the previous annual report, indicating instability in business operations.

Balance Sheet

The balance sheet reflects a strong equity position with no debt, which is a positive aspect in terms of financial stability. However, the declining asset base and stockholders' equity over time raise concerns about the company's ability to sustain operations and growth. The equity ratio remains favorable, but the overall financial health is at risk if operational losses continue.

Cash Flow

The cash flow statement highlights significant negative free cash flow and operating cash flow, indicating liquidity issues and challenges in covering operational expenses. The absence of debt is a positive factor, but the consistent cash outflows could constrain future investments and operational scalability.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	49.00K	49.00K	60.00K	0.00	110.00K	0.00
Gross Profit	49.00K	49.00K	-346.00K	-446.00K	70.00K	-430.19K
EBITDA	-3.16M	-3.16M	-2.78M	-6.89M	-9.29M	-4.77M
Net Income	-7.47M	-7.47M	-7.67M	-7.44M	-9.71M	-8.14M
Balance Sheet
Total Assets	2.74M	2.74M	8.97M	16.77M	25.27M	31.61M
Cash, Cash Equivalents and Short-Term Investments	1.72M	1.72M	5.92M	9.71M	14.22M	19.51M
Total Debt	0.00	0.00	0.00	6.00K	44.00K	84.00K
Total Liabilities	209.00K	209.00K	258.00K	591.00K	422.00K	1.11M
Stockholders Equity	2.53M	2.53M	8.71M	16.18M	24.85M	30.50M
Cash Flow
Free Cash Flow	-3.91M	-3.91M	-3.80M	-4.85M	-5.68M	-4.31M
Operating Cash Flow	-3.90M	-3.90M	-3.30M	-4.79M	-5.59M	-3.86M
Investing Cash Flow	-290.00K	-290.00K	-503.00K	1.89M	-98.00K	-149.00K
Financing Cash Flow	0.00	0.00	-6.00K	-1.60M	395.00K	21.78M

Mountain Valley MD Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.02
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MVMD, the sentiment is Positive. The current price of 0.02 is below the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.02, and below the 200-day MA of 0.02, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 52.07 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:MVMD.

Mountain Valley MD Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MVMD	46 Neutral	C$5.29M	-0.71	-148.48%	―	-46.59%	8.26%
LOBE	46 Neutral	C$17.52M	-2.93	―	―	-100.00%	-8.70%
RVV	44 Neutral	C$6.28M	-0.58	-664.21%	―	―	-80.42%
PCLO	44 Neutral	C$15.39M	-2.79	―	―	15.64%	58.47%
CANB	41 Neutral	C$3.46M	-2.69	-11.42%	―	-5.87%	-239.53%
AYUR	38 Underperform	C$3.89M	-0.89	-271.33%	―	15.95%	-1.81%

Mountain Valley MD Corporate Events

Mountain Valley MD Details Year-End Commercialization Gains Across Core Platforms

Mountain Valley MD issued a year-end update highlighting commercialization progress across its three main platforms, with management emphasizing disciplined execution in product development, field validation and commercial foundations as the business enters a new growth phase. In nutraceuticals, the company is scaling its Quicksome™ technology through an exclusive U.S.-based GMP manufacturing partner, supporting ongoing production for Circadian Wellness’s Quicksome™-based Eons sublingual products and advancing new licensing opportunities in areas such as menopause symptom relief, muscle recovery, anti-inflammation and joint health, while preparing a fenugreek glycosides testosterone product launch via a licensee in the first half of 2026 and positioning its “Mountains Of…” branded line for either direct or white-label distribution; in agriculture, MVMD continues to validate and commercialize its Agrarius technology across diverse crops and regions, reinforcing its potential role in sustainable farming and laying a data-driven foundation for longer-term adoption.

The most recent analyst rating on (TSE:MVMD) stock is a Hold with a C$0.02 price target. To see the full list of analyst forecasts on Mountain Valley MD stock, see the TSE:MVMD Stock Forecast page.

Mountain Valley MD Advances Agrarius Product with Positive Trial Results

Mountain Valley MD has announced positive results from its Agrarius agricultural product trials in Brazil and Colombia, which are crucial for its commercialization strategy. The trials in Brazil showed significant improvements in citrus yield and plant health, particularly in reducing symptoms of citrus greening disease. In Colombia, the trials indicated enhanced pasture grass productivity and nutritional quality, suggesting potential benefits for the livestock sector. These findings support the company’s expansion objectives and highlight Agrarius as a promising tool for improving agricultural productivity and sustainability.